Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, <scp>OCTAVE</scp> open-Reference-Cited by-同舟云学术

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open

Published:2022-03-05 Issue:12 Volume:55 Page:1534-1544
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Panaccione Remo¹^ORCID,Abreu Maria T.²,Lazariciu Irina³,Mundayat Rajiv³,Lawendy Nervin⁴,Salese Leonardo⁴,Woolcott John C.⁴,Sands Bruce E.⁵,Chaparro María⁶^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Medicine University of Calgary Calgary Alberta Canada

2. Department of Medicine, Division of Gastroenterology, Crohn’s and Colitis Center University of Miami Miller School of Medicine Miami Florida USA

3. Pfizer Inc New York New York USA

4. Pfizer Inc Collegeville Pennsylvania USA

5. Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai New York New York USA

6. Gastroenterology Department of Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS‐IP) Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Madrid Spain

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16848

Reference23 articles.

1. Ulcerative colitis

2. ACG Clinical Guideline: Ulcerative Colitis in Adults

3. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management